Target intelligence / Profile preview

Methyl-CpG binding domain protein 3-like 2 (MBD3L2)

Target
MBD3L2
Molecular classification
Other (homolog of the methyl-CpG binding domain protein family but lacks the canonical methyl-CpG-binding domain)
01

Overview

Methyl-CpG binding domain protein 3-like 2 (MBD3L2) is a protein-coding gene related to the methyl-CpG-binding protein family but notably lacks the methyl-CpG-binding domain required for binding methylated DNA. It is homologous to MBD2 and MBD3 and can interact with MBD3 and components of the nucleosome remodeling and histone deacetylase (NuRD) complex. MBD3L2 acts as a transcriptional repressor when tethered to DNA and may modulate the recruitment of the NuRD complex, potentially relieving or reinforcing repression depending on context. Its expression is developmentally regulated, notably enriched in germ cells and early embryos in mice, and has been detected in human germ cell tumors and select somatic tissues. While implicated in chromatin regulation and transcriptional modulation, it is not a conventional therapeutic target (receptor, enzyme, transporter, etc.), and there is currently no evidence linking it to drug interactions, biomarker utility, or specific safety concerns.

Other names
MBD3L2Methyl-CpG-binding domain protein 3-like 2MBD3-like protein 2CTB-25J19.1
02

Biological functions

Regulation of chromatin organizationRegulation of transcription (transcriptional repression/modulation)
03

Disease associations

Digenic diseaseFacioscapulohumeral muscular dystrophy 1 (association from gene/disease resources, not necessarily causative)

Beyond the preview

Go deeper on Methyl-CpG binding domain protein 3-like 2 (MBD3L2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Methyl-CpG binding domain protein 3-like 2 (MBD3L2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call